Friend or Foe: How COVID-19 Changed the Dynamic with Global Regulatory Agencies

COVID-19 lit a fire under global regulatory systems, triggering regulatory bodies and pharma companies to prioritize and streamline their development efforts. Despite the industry’s commitment to safety and efficacy, fast-tracked R&D and market authorization bred hesitancy toward COVID-19 vaccines, impacting vaccine access and uptake. In this session, experts will explore the regulatory challenges underpinning the swift roll-out of COVID-19 vaccines, resulting obstacles in vaccine confidence and adoption, and opportunities for better collaboration between sponsors and regulators at the forefront. With an increased understanding of COVID-19 through real-world evidence, these learnings and evolving partnerships present an opportunity to carry lessons learned forward for future treatments and technologies.